Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors
- Bioorg Med Chem. 2017 Oct 15;25(20):5268-5277. doi: 10.1016/j.bmc.2017.07.049.
- 1. School of Pharmacy, East China University of Science & Technology, 130 Meilong Road, Shanghai 200237, People's Republic of China; Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People's Republic of China.
- 2. Department of Medicinal Chemistry, School of Pharmacy, Fourth Military Medical University, 169 Changle West Road, Xi'an 710032, People's Republic of China.
- 3. Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People's Republic of China.
- 4. School of Pharmacy, East China University of Science & Technology, 130 Meilong Road, Shanghai 200237, People's Republic of China.
- 5. School of Pharmacy, East China University of Science & Technology, 130 Meilong Road, Shanghai 200237, People's Republic of China. Electronic address: [email protected].
- 6. Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People's Republic of China. Electronic address: [email protected].
p53-MDM2 protein-protein interaction is a promising target for novel antitumor drug development. Previously, we identified a new class of spirotetrahydrothiopyran-oxindole p53-MDM2 inhibitors by novel organocatalytic enantioselective cascade reactions. Herein, a series of new derivatives were designed, synthesized and assayed to investigate the structure-activity relationships. Among them, compound B14 bearing a novel spiroindole-thiopyranopyridone scaffold exhibited potent MDM2 inhibitory activity as well as antitumor activity, which could effectively induce the Apoptosis of A549 Cancer cells. It represents a promising lead compound for the development of novel antitumor agents.